Prostate Cancer - Results from #24160

Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer - Abstract February 21, 2013

Tasquinimod: A novel angiogenesis inhibitor-development in prostate cancer - Abstract February 21, 2013

Enzalutamide, a second generation androgen receptor antagonist: Development and clinical applications in prostate cancer - Abstract February 21, 2013

GU Cancers Symposium 2013 - Exploratory analysis of the visceral disease patient subset in COU-AA-301, a phase 3 study of abiraterone acetate in metastatic castration-resistant prostate cancer, by Oscar B. Goodman Jr., MD, PhD, et al. - Poster February 21, 2013

Bone metastases from prostate cancer: 18F-fluoride PET/CT in a patient with discordant bone scintigraphy and 11C-choline PET/CT - Abstract February 21, 2013

Low rectal toxicity after dose escalated IMRT treatment of prostate cancer using an absorbable hydrogel for increasing and maintaining space between the rectum and prostate: Results of a multi-institutional phase II trial - Abstract February 21, 2013

Spacer stability and prostate position variability during radiotherapy for prostate cancer applying a hydrogel to protect the rectal wall - Abstract February 21, 2013

Cost of prostate image-guided radiation therapy: Results of a randomized trial - Abstract February 21, 2013

Partial delegation to radiation therapists of the control by onboard imaging of patient positioning - Abstract February 21, 2013

Rapid and specific electrochemical detection of prostate cancer cells using an aperture sensor array - Abstract February 21, 2013

High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers - Abstract February 21, 2013

Targeted prostate biopsies for a histogram of the index lesion - Abstract February 21, 2013

GU Cancers Symposium 2013 - Real-world experience with sipuleucel-T in metastatic castration-resistant prostate cancer patients ≥ 80 years-old: Data from PROCEED - Session Highlights February 21, 2013

GU Cancers Symposium 2013 - Immune response to sipuleucel-T in patients with metastatic castrate-resistant prostate cancer (mCRPC): Phase 2 ProACT study, by Thomas A. Gardner, MD, et al. - Session Highlights February 20, 2013

GU Cancers Symposium 2013 - Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE) February 20, 2013

GU Cancers Symposium 2013 - A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate in metastatic castrate-resistant prostate cancer, by Eric J. Small, MD, et al. - Podcast February 20, 2013

GU Cancers Symposium 2013 - Trans-Pacific variation in outcomes for men treated with primary androgen deprivation therapy for localized prostate cancer, by Matthew R. Cooperberg, MD, MPH, et al. - Session Highlights and Podcast February 20, 2013

GU Cancers Symposium 2013 - Open-label, multicenter study of sipuleucel-T in metastatic castrate-resistant prostate cancer patients previously treated with sipuleucel-T: Evaluation of androgen-presenting cell activation, by L. Michael Glode, MD, et al. February 20, 2013

GU Cancers Symposium 2013 - Utilization of cancer detection by U.S. prostate biospies (2005-2011), by Carl A. Olsson, MD, et al. - Session Highlights and Podcast February 20, 2013

GU Cancers Symposium 2013 - The ERα agonist, GTx-758, decreases bone turnover markers in men with advanced prostate cancer, by Evan Y. Yu, MD, et al. - Poster February 20, 2013

Page 1209 of 1454